RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: A human genome epidemiologic review and meta-analysis of observational studies
Reduced Folate Carrier Protein
In these analyses of available data from observational studies, RFC1 80G>A was found to be associated with MTX efficacy, but not toxicity, in RA patients. This variant merits further prospective analysis as a potential predictor of MTX efficacy. Variability in the definitions of response in pharmacogenetic studies is a source of data heterogeneity that should be addressed.